• Company
• Anti-cancer drug trends changes from IV→SC
• by Moon, sung-ho Aug 30, 2024 05:50am

• Company
• K-bio jumps into developing new drugs for pancreatic cancer
• by Son, Hyung-Min Aug 30, 2024 05:50am

• Company
• Korean pharma and biotechs expand R&D investments
• by Chon, Seung-Hyun Aug 29, 2024 04:32am

• Company
• Breast cancer drug Trodelvy receives DREC deliberations
• by Eo, Yun-Ho Aug 29, 2024 04:31am

• Company
• "Switching of atopic dermatitis treatments not yet allowed"
• by Hwang, Byung-woo Aug 28, 2024 05:52am

• Company
• K-made Leclaza monotherapy to be showcased at global meeting
• by Son, Hyung-Min Aug 28, 2024 05:52am

• Company
• Challenges in the evolving lung cancer treatment landscape
• by Son, Hyung-Min Aug 28, 2024 05:51am

• Company
• Value of new drugs should be evaluated based on efficacy
• by Hwang, Byung-woo Aug 27, 2024 05:50am

• Company
• K-similars won record number of U.S.·Europe nods this year
• by Chon, Seung-Hyun Aug 27, 2024 05:50am

• Company
• More urothelial cancer drug options now available in KOR
• by Hwang, Byung-woo Aug 26, 2024 05:46am